Chimeric Therapeutics Ltd

CHM

Company Profile

  • Business description

    Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.

  • Contact

    62 Lygon Street
    Level 3, Carlton
    MelbourneVIC3053
    AUS

    T: +61 398245254

    https://www.chimerictherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

Plunge in ASX share unwarranted

Weak result distracts from improving trading and cost outlook.
stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,057.6048.70-0.53%
CAC 407,850.3021.72-0.28%
DAX 4023,584.5826.75-0.11%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,212.4110.91-0.12%
HKSE26,518.65359.531.37%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,630.31136.650.30%
NZX 50 Index13,181.3144.770.34%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,764.5050.50-0.57%
SSE Composite Index3,853.6431.810.83%

Market Movers